- FDA’s radical transparency policy for rejections runs into legal uncertaintyHaving started to publish CRLs without consulting the public, the FDA is under pressure to change course amid concerns it failed to openly and fully evaluate a complex issue.BioSpace · 3d ago↗ source
- Genetic medicine luminaries launch new center for personalized therapiesA team of veteran scientists from elite institutions has come together to form a new center dedicated to the crafting of personalized genetic medicines, adding to the growing list of similar effort…Fierce Biotech · 3d ago↗ source
- 2026 IPO class blooms again as BlossomHill, Latigo set sights on NasdaqEighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the pandemic-driven high of 2021.